Author: Hualong Xiong; Yangtao Wu; Jiali Cao; Ren Yang; Jian Ma; Xiaoyang Qiao; Xiangyang Yao; Baohui Zhang; Yali Zhang; Wangheng Hou; Yang Shi; Jingjing Xu; Liang Zhang; Shaojuan Wang; Baorong Fu; Ting Yang; Shengxiang Ge; Jun Zhang; Quan Yuan; Baoying Huang; Zhiyong Li; Tianying Zhang; Ningshao Xia
Title: Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells Document date: 2020_4_9
ID: fvjh3g7v_14
Snippet: To compare the infection efficiency of pseudotypes bearing different glycosylated protein, single cycle infectious recombinant VSVdG-EGFP-G was prepared and used to infect Vero-E6 cells transiently expressing full-length SARS-CoV-2-S protein and truncated SARS-CoV-2-Sdel18 protein that with C-terminal 18 aa truncation respectively, pseudotyped VSV-SARS-CoV-2-S and VSV-SARS-CoV-2-Sdel18 was obtained following the procedures described in methods ( .....
Document: To compare the infection efficiency of pseudotypes bearing different glycosylated protein, single cycle infectious recombinant VSVdG-EGFP-G was prepared and used to infect Vero-E6 cells transiently expressing full-length SARS-CoV-2-S protein and truncated SARS-CoV-2-Sdel18 protein that with C-terminal 18 aa truncation respectively, pseudotyped VSV-SARS-CoV-2-S and VSV-SARS-CoV-2-Sdel18 was obtained following the procedures described in methods ( Figure 1 ). Vero-E6, BHK21, BHK21-hACE2 and 293T cells were seeded to compare the infection efficiency of pseudotypes. The infection efficiency of VSV pseudotypes bearing truncated Sdel18 was much higher than that with full-length S protein. The results suggested that the combination of VSV-SARS-CoV-2-Sdel18 and BHK21-hACE2 cells could be a better alternation for establishing pseudotyped SARS-CoV-2 entry and neutralization assays.
Search related documents:
Co phrase search for related documents- aa truncation and length SARS protein: 1
- aa truncation and neutralization assay: 1
- aa truncation and SARS protein: 1, 2
- aa truncation and VSV SARS cell: 1
- different glycosylated protein and glycosylated protein: 1, 2, 3, 4
- different glycosylated protein and SARS protein: 1
- glycosylated protein and length SARS protein: 1, 2, 3, 4, 5, 6, 7
- glycosylated protein and neutralization assay: 1
- glycosylated protein and SARS entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- glycosylated protein and SARS protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- infection efficiency and length SARS protein: 1, 2
- infection efficiency and neutralization assay: 1, 2, 3, 4, 5
- infection efficiency and pseudotype infection efficiency: 1
- infection efficiency and SARS entry: 1, 2, 3, 4, 5, 6, 7
- infection efficiency and SARS protein: 1, 2, 3, 4, 5, 6, 7, 8
- infection efficiency and VSV SARS cell: 1
- length SARS protein and neutralization assay: 1, 2, 3, 4, 5, 6
- length SARS protein and SARS entry: 1, 2, 3, 4, 5, 6, 7
- length SARS protein and SARS protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
Co phrase search for related documents, hyperlinks ordered by date